Evidence map›Paper›PMID 29915719›Full record

ReviewFrontiers in oncology2018

Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

Timothy M Pierpont, Candice B Limper, Kristy L Richards

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. T cell engagers in autoimmune diseases.Nature reviews. Immunology · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Role of Monoclonal Antibodies in Alzheimer's Disease: Successes, Failures, and Future Directions.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  20. Article

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Timothy M PierpontRichards Laboratory, Department of Biomedical Sciences, Cornell University, Ithaca, NY, United States.
Candice B LimperRichards Laboratory, Department of Biomedical Sciences, Cornell University, Ithaca, NY, United States.
Kristy L RichardsRichards Laboratory, Department of Biomedical Sciences, Cornell University, Ithaca, NY, United States.

Funding

(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodiesR01CA185372 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RICHARDS, KRISTY L · 2014 to 2017
$1.3M
NCI NIH HHS R01 CA185372
6 · The paper itself

Abstract

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $8.58 billion in 2016. Since its initial approval in 1997, it has improved outcomes in all B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia. Despite widespread use, most mechanistic data have been gathered from

Indexed as

cancerimmunotherapylymphomamonoclonal antibodyrituximab

Identifiers

PMID29915719
PMCPMC5994406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.